SNX16 activates c-Myc signaling by inhibiting ubiquitin-mediated proteasomal degradation of eEF1A2 in colorectal cancer development

Zhiyong Shen¹, Yongsheng Li¹, Yuan Fang², Mingdao Lin¹, Xiaochuang Feng¹, Zhenkang Li¹, Yizhi Zhan³, Yuechen Liu¹, Tingyu Mou¹, Xiaoliang Lan¹, Yanan Wang¹, Guoxin Li¹, Jiping Wang⁴ and Haijun Deng¹

¹ Department of General Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China
² Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China
³ Department of Pathology, Nanfang Hospital, Southern Medical University, Guangzhou, China
⁴ Division of Surgical Oncology, Department of Surgery, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA

Keywords
- cell proliferation; c-Myc; colorectal cancer; eEF1A2; SNX16

Correspondence
G. Li, H. Deng, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong Province 510515, China
Tel: +86 20 62787170
E-mail: gzliguoxin163.com (GL); navyd999@163.com (HD)
J. Wang, Division of Surgical Oncology, Department of Surgery, Brigham and Women’s Hospital, Harvard Medical School, 75 Francis St., Boston, MA 02115, USA
Tel: +617 732 8449
E-mail: jwang39@bwh.harvard.edu

Zhiyong Shen, Yongsheng Li and Yuan Fang contributed equally to this work.

(Received 22 September 2019, revised 1 December 2019, accepted 2 December 2019, available online 10 January 2020)
doi:10.1002/1878-0261.12626

1. Introduction

Colorectal cancer (CRC) is the third most common cancer worldwide and was associated with 881,000 cancer-related deaths in 2018 (Bray et al., 2018). The initiation and development of CRC involves successive accumulation of genetic and epigenetic alterations that lead to a multistep and stepwise progression from...
normal mucosa to dysplasia and finally to carcinoma (Kuipers et al., 2015; Luo et al., 2013). Approximately eighty percent of CRC tumors can be distinguished by the accumulation of alterations in specific oncogenes (e.g., APC, KRAS, PIK3CA, SMAD4) and tumor suppressor genes, which thereby activate pathways that are critical for CRC tumorigenesis (Muller et al., 2016). Aberrant activation of oncogenes is a key driver of uncontrolled cell proliferation in tumors (Nagarajan et al., 2016). Thus, identification of novel oncogenes that are aberrantly overexpressed in CRC may provide insights into the oncogenic mechanisms underlying uncontrolled cell proliferation and lead to the discovery of new potential biomarkers for prognosis, diagnosis, and treatment of CRC patients.

Sorting nexins (SNXs) are a diverse group of proteins that contain the SNX-PX domain and play a key role in membrane trafficking (Teasdale and Collins, 2012; Worby and Dixon, 2002). Some studies have shown that SNXs are also involved in the regulation of important signaling pathways associated with cancers. It is reported that SNX3 mediated intracellular cycling of the Wnt receptor Wntless (Harterink et al., 2011). In addition, studies have shown that the expression levels of SNXs are closely related to the EGFR content in cells. In some tumors, high expression of SNXs can inhibit EGFR degradation (Chiow et al., 2012; Liu et al., 2006). Sorting nexin 16 (SNX16), a member of SNX family, is associated with vesicular K1 inflammatory virus infection, hepatitis C virus replication (Le Blanc et al., 2005), and synaptic growth receptor transport (Blackham et al., 2010). SNX16 has been implicated in the development of various tumors. SNX16 was found to be overexpressed in the blood cells of bladder cancer patients (Osman, 2006). In addition, SNX16 levels were significantly higher in ovarian cancer tissue than in normal tissues (Pharoah et al., 2013). Previous studies have also suggested that SNX16 exhibited alternative splicing in certain melanoma cell lines and could interact with 32 SNPs that are known risk factors for prostate cancer (Tao et al., 2012; Watahiki et al., 2004). However, the expression and biological function of SNX16 with regard to CRC has not been thoroughly investigated.

c-Myc is a well-established cancer driver gene that plays essential roles in multiple biological processes including cell proliferation, cell growth, apoptosis, and energy metabolism (Dang, 2012; Gong et al., 2018). Constitutive upregulation of c-Myc is believed to be the basis of a variety of tumors, including CRC (Gong et al., 2018). However, to the best of our knowledge, the mechanism by which SNX16 regulates c-Myc signaling to control of cell proliferation in CRC has never been reported.

Here, for the first time, we evaluated the expression pattern and clinical significance of SNX16 in CRC, aiming to elucidate the functions and molecular mechanisms of SNX16 both in vitro and in vivo. Our study provides new mechanistic insights into the crucial roles of SNX16 in the activation of c-Myc signaling via inhibition of eukaryotic translation elongation factor 1A2 (eEF1A2) ubiquitination, providing a potential marker and novel intervention targets for CRC.

2. Materials and methods

2.1. Patient samples and cell culture

This study was approved by the Institutional Research Medical Ethics Committee of Nanfang Hospital. The experiments were undertaken with the understanding and written consent of each participant, which was in accordance with the Declaration of Helsinki. All human CRC tissue samples were collected from the Department of General Surgery, Nanfang Hospital, Southern Medical University. Twenty pairs of CRC specimens (CRC and adjacent nontumor tissues) were used for quantitative real-time PCR (qRT-PCR). Nine pairs of CRC specimens were used for western blot analyses. Fifteen paired CRC and adjacent normal tissues were used for immunohistochemical (IHC) analysis. A tissue microarray (TMA), involving a total of 193 CRC patients who underwent colorectal resections from November 2013 to June 2014 in Nanfang Hospital, Southern Medical University (Guangzhou, China), was used to analyze the correlations among SNX16, eEF1A2, and c-Myc expression.

The datasets used were downloaded from the public Gene Expression Omnibus (GEO) and Oncomine (www.oncomine.org) databases. We evaluated the correlation of SNX16 expression levels with patient survival in CRC using the R2: Genomics Analysis and Visualization Platform (a biologist friendly Web-based genomics analysis and visualization application; http://r2.amc.nl). CRC cell lines (SW1116, HT29, 174T, CaCO2, HCT115, DLD1, SW480, RKO, SW620, LoVo, HCT116) were obtained from the American Type Culture Collection (Manassas, VA, USA).

2.2. Western blot analysis and quantitative real-time PCR

Proteins were separated on SDS/PAGE gels and transfer to polyvinylidene fluoride membranes. The membranes were incubated with different primary antibody (Table S2) in TBS-Tween 20 at 4 °C overnight. Following
incubation with the appropriate secondary antibody, the membranes were visualized using the Luminata Chemiluminescent Detection Kit (Millipore, Burlington, MA, USA). Total RNA extraction and qRT-PCR were performed, as previously described (Shen et al., 2019b).

2.3. Immunohistochemical analysis

Human CRC tissue samples and mice subcutaneous tumor samples were fixed in 4% paraformaldehyde for 24 h and were embedded in paraffin; 5-μm-thick sections were prepared for IHC staining. Deparaffinized sections were quenched to eliminate endogenous peroxidase activity, followed by antigen retrieval and blocking procedures. Then, the slices were incubated with different primary antibodies at 4°C overnight. Subsequently, the slices were incubated with biotinylated secondary antibody and visualized using a DAB kit.

To evaluate the results, two individuals scored all the sections independently. The final IHC scores were generated by combining the scores for the proportion of positive tumor cells and the intensity of staining (Ni et al., 2017). The proportion score was determined as follows: 0, no positive tumor cells; 1, 1–25%; 2, 26–50%; 3, 51–75%; 4, >75%. The intensity of staining was evaluated as follows: 0, no staining; 1, weak staining; 2, intermediate staining; 3, strong staining. The comprehensive IHC score was calculated by multiplying the proportion score by the staining intensity score. When the SNX16 expression score was higher than the average score, the SNX16 expression in these CRC samples was defined as high; otherwise, it was defined as low.

2.4. Cell transfection

An optimized SNX16-knockdown lentivirus expressing LV-SNX16-RNAi (sh-SNX16; GeneChem, Shanghai, China) was used to transfect HT29 and LoVo cells. Cells were transfected with empty lentivirus as a negative control (sh-NC). The SNX16-overexpressing cell line was constructed using the SNX16-overexpressed vectors (LV-SNX16), and a NC (LV-NC) cell line was also generated. Transfection procedures were performed according to the manufacturer’s instructions.

2.5. Cell proliferation assay and colony formation assay

Cell growth was determined using the MTT assay (Sigma, St. Louis, MO, USA) according to the manufacturer’s instructions. A total of 1 × 10^5 transfected cells per well were seeded into 96-well plates, and cell viability was assessed every 24 h following the manufacturer’s protocol. EdU assays were used to examine the effect of SNX16 on DNA replication. The cells were treated with 50 μM of 5-ethynyl-2'-deoxyuridine (Ribobio, Guangzhou, China) for 2 h and processed according to the manufacturer’s instruction. Then, the DNA contents of the cells were stained with Hoechst33342 and visualized by a fluorescence microscope. For the colony formation assay, transfected cells were seeded into six-well plates. At the end of experiments, colonies were fixed with methanol and stained with 0.1% crystal violet (Leagene, Beijing, China).

2.6. Flow cytometry

Transfected cells were harvested after 5-Fu (40 μg·mL⁻¹) treatment for 48 h. Cells were collected and apoptosis was detected by using the Annexin V-APC/PI Apoptosis Detection Kit (KeyGen Biotech, Nanjing, China). For cell cycle analysis, cells were incubated with RNase and PI staining using the Cell Cycle Detection Kit. The detailed procedures were performed according to instructions provided (KeyGen Biotech).

2.7. Animal models

To evaluate in vivo tumorigenesis, 5 × 10^6 transfection cells were subcutaneously injected into the left or right flanks of 4-week-old nude mice (five mice in each group). The tumor size was measured every 3 days, and the tumor volume was calculated as (length × width^2)/2 (Shen et al., 2019b). All nude mice were obtained from Laboratory Animal Center of Southern Medical University. All animal experiments were approved by the Animal Care and Use Committee of Southern Medical University.

2.8. Co-immunoprecipitation and mass spectrometry

The total protein from HT29 cells was extracted in radioimmunoprecipitation assay buffer supplemented with proteinase/phosphatase inhibitors. Total cell extracts were incubated with anti-SNX16 (Santa Cruz, MA, USA) and IgG (as a negative control) with gentle shaking overnight at 4 °C, followed by the addition of protein A/G-agarose beads (Thermo Scientific, Waltham, MA, USA) for an additional 4 h. The beads were washed and resuspended in PBS and 5× loading buffer and boiled for 5 min. The proteins were separated by SDS/PAGE, followed by silver staining. Candidate bands were subjected to mass spectrometric analysis for protein identification.
2.9. Immunofluorescence staining

Cells were fixed in a 4% paraformaldehyde solution, and 0.5% Triton solution was added to disrupt the cytomembrane. After blocking in 1% BSA at room temperature for 20 min, the cells were incubated with primary antibodies of interest at 4 °C overnight. After washing with PBS three times, a fluorescent secondary antibody and 4',6-diamidino-2-phenylindole staining kit were used in the dark to detect the bound primary antibody and cell nuclei, respectively. The cells were observed under an inverted microscope.

2.10. Ubiquitination assay

SNX16-knockdown HT29 cells or SNX16-overexpressing SW480 cells and control cells were treated with 30 μM MG132 for 12 h to block proteasomal degradation. The lysates were immunoprecipitated with anti-eEF1A2 (Proteintech, Rosemont, IL, USA) antibodies or anti-IgG on protein A/G beads (Thermo Scientific) overnight at 4 °C with rotation and then boiled in SDS buffer. Eluates were subjected to western blotting using anti-K48-linked poly-ubiquitination antibody to evaluate the proteasome-dependent ubiquitination level.

2.11. Statistical analysis

Statistical analysis was carried out with spss 22.0 (SPSS Inc., Chicago, IL, USA) statistical software package or GRAPHPAD PRISM 7.0 software (GraphPad Software Inc., San Diego, CA, USA). T-tests were used to evaluate differences between two groups of variables. Survival curves were obtained by the Kaplan–Meier survival analysis. Cox proportional hazards regression was used to identify independent factors that have a significant impact on patient survival. Correlations among SNX16 expression, eEF1A2 expression, and c-Myc expression in the TMA were analyzed with Spearman’s rank correlation. Probability values from the two-tailed test that were < 0.05 were considered significant.

3. Results

3.1. SNX16 is overexpressed in colorectal cancer and is correlated with poor prognosis

To explore the expression of SNX16 in CRC, we first analyzed SNX16 expression levels in normal and CRC tissues by bioinformatics analysis. Microarray data from Oncomine and the public GEO database (GSE18105, GSE32323, and GSE44861) revealed that SNX16 was significantly upregulated in tumors compared to normal tissues (Fig. 1A,B; Fig. S1). Consistent with the publicly available data, qRT-PCR (n = 20), western blot analysis (n = 9), and IHC analysis (n = 15) showed that the mRNA and protein levels of SNX16 were similarly elevated in CRC tissues compared to the corresponding adjacent normal mucosa (Fig. 1C–E).

Finally, we investigated the clinical relevance of SNX16 by using public datasets. The results of the Kaplan–Meier survival analysis suggested that patients with high SNX16 expression levels (P = 0.019) had adverse clinical outcomes among 232 CRC patients from the GEO database (GSE17538; Fig. 1F), especially in stage III (P = 0.048) or IV (P = 0.007) patients with CRC but not in stage I (P = 0.938) or II (P = 0.569) patients (Fig. 1G–J). Univariable Cox regression model analysis revealed that poor differentiation (hazard ratio, HR: 1.52; 95% confidence interval, 95% CI: 1.168–1.966; P = 0.002), advanced clinical stage (HR: 2.73; 95% CI: 2.087–3.558; P = 0.000), and high SNX16 expression (HR: 1.64; 95% CI: 1.079–2.500; P = 0.021) were significantly associated with poor survival. Furthermore, multivariable Cox regression analysis revealed that high SNX16 expression is an independent prognostic factor for poor survival (HR: 1.75, 95% CI: 1.113–2.737; P = 0.015; Table 1). Additionally, we analyzed the prognostic value of SNX16 for CRC patients using the R2: Genomics Analysis and Visualization Platform (http://r2.amc.nl). High expression of SNX16 was associated with poor overall survival and relapse-free survival time (Fig. S2).
Z. Shen et al.

SNX16 promotes colorectal cancer development

**A**

Kaiser colon vs. Hong Colorectal

log2 median-centered intensity

Normal Tumor Normal Tumor
n = 5 n = 76 n = 12 n = 70

**B**

Relative mRNA expression

GSE18105 GSE32332 GSE44861

Normal Tumor Normal Tumor Normal Tumor
n = 17 n = 94 n = 17 n = 17 n = 56 n = 57

**C**

Relative mRNA expression

Normal Tumor

**D**

SNX16 Tubulin

1N 1T 2N 2T 3N 3T 4N 4T 5N 5T 6N 6T 7N 7T 8N 8T 9N 9T

kDa

–39

–55

**E**

Adjacent normal Tumor

Case 1 Case 2

200 µm

200 µm

50 µm

50 µm

50 µm

50 µm

GSE17538

**F**

GSE17538

Low (n = 113) High (n = 119)

n = 232

P = 0.019

**G**

Stage I

High (n = 12)

Low (n = 16)

SNX16 expression

Low

High

Low-censored

High-censored

P = 0.938

Time (months)

Percentage survival

0 20 40 60 80 100 120 140

0.0 0.5 1.0

**H**

Stage II

High (n = 34)

Low (n = 38)

SNX16 expression

Low

High

Low-censored

High-censored

P = 0.569

Time (months)

Percentage survival

0 20 50 75 100 125

0.0 0.5 1.0

**I**

Stage III

High (n = 43)

Low (n = 33)

SNX16 expression

Low

High

Low-censored

High-censored

P = 0.048

Time (months)

Percentage survival

0 20 40 60 80 100 120

0.0 0.5 1.0

**J**

Stage IV

High (n = 29)

Low (n = 27)

SNX16 expression

Low

High

Low-censored

High-censored

P = 0.007

Time (months)

Percentage survival

0 20 50 75 100 125

0.0 0.5 1.0

Molecular Oncology 14 (2020) 387–406 © 2019 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
3.2. SNX16 promotes colorectal cancer cells proliferation in vitro

Given previous results, we further evaluated the functional role of SNX16 in CRC cells. We first analyzed the endogenous levels of SNX16 expression in 11 CRC cell lines by qRT-PCR and western blotting (Fig. S3). HT29 and LoVo cells with relatively high endogenous SNX16 expression were selected to establish stable SNX16 knockdown cell lines, while SW480 cells with low endogenous SNX16 expression were selected to establish stable SNX16-overexpressing cell lines (Fig. 2A, B). As evidenced by MTT assays, EdU assays and colony formation assays, knockdown of SNX16 expression in HT29 and LoVo cells significantly inhibited cell growth. Conversely, ectopic expression of SNX16 in SW480 cells promoted cell proliferation and viability (Fig. 2C–E; Fig. S4). However, transwell assays showed that the downregulation or upregulation of SNX16 had no significant effect on the migration capacity of CRC cells compared with control cells (Fig. S5).

3.3. Knockdown of SNX16 induces cell cycle arrest and apoptosis in colorectal cancer cells

To investigate the mechanism underlying decreased cell proliferation in SNX16-knockdown HT29 and LoVo cells, the effect of SNX16 knockdown on cell cycle progression was analyzed by flow cytometry. Our results revealed that knockdown of SNX16 in HT29 and LoVo cells significantly decreased the S-phase cell population and increased the G0 to G1 phase cell population but increased the G0 to G1 phase cell population. Conversely, ectopic expression of SNX16 in SW480 cells promoted cell proliferation and viability (Fig. 2F). In contrast, ectopic expression of

| Variable               | All casea | Univariable analysisb | Multivariable analysisb |
|------------------------|-----------|-----------------------|-------------------------|
|                        |           | HR (95% CI)           | P-value                 |
| Gender                 |           |                       |                         |
| Male                   | 122       | 1.035 (0.689–1.555)   | 0.869                   |
| Female                 | 110       |                       |                         |
| Age (years)            |           |                       |                         |
| < 65                   | 110       | 1.062 (0.707–1.596)   | 0.772                   |
| ≥ 65                   | 122       |                       |                         |
| Differentiationc       |           |                       |                         |
| Well/moderate          | 183       | 1.515 (1.168–1.966)   | 0.002                   |
| Poor                   | 30        |                       |                         |
| TNM stage              |           |                       |                         |
| I                      | 28        | 2.725 (2.087–3.558)   | 0.000                   |
| II                     | 72        |                       |                         |
| III                    | 76        |                       |                         |
| IV                     | 56        |                       |                         |
| SNX16 expression       |           |                       |                         |
| Low expression         | 113       | 1.642 (1.079–2.500)   | 0.021                   |
| High expression        | 119       |                       |                         |

aSix cases missing follow-up data
bCox regression model (method = Enter)
cNineteen cases missing Differentiation data.

---

392 Molecular Oncology 14 (2020) 387–406 © 2019 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
Z. Shen et al.  
SNX16 promotes colorectal cancer development

**A**  
HT29  
LoVo  
SW480  
Relative mRNA expression

**B**  
HT29  
LoVo  
SW480  
SNX16  
GAPDH

**C**  
HT29  
LoVo  
Absolute OD 570 nm

**D**  
HT29  
LoVo  
SW480  
Edit positive cells (%)

**E**  
HT29  
LoVo  
SW480  
Number of colonies

**F**  
HT29  
LoVo  
SW480  
Cell population (%)

**G**  
HT29  
LoVo  
SW480  
Leukemia cell apoptosis

**H**  
HT29  
LoVo  
SW480  
p21, p18, CDK6, cyclin D3, cyclin D1, Tubulin

**I**  
HT29  
LoVo  
SW480  
Cleaved Caspase3, Caspase3, Tubulin
SNX16 in SW480 cells significantly decreased the cell population in the G0 to G1 phase but increased the S-phase cell population. Furthermore, we analyzed kinetic of cell cycle progression after releasing cancer cells from G1 phase synchronously and obtained similar results (Fig. S5).

To further explore the underlying molecular mechanisms that promote G1 to S transition mediated by SNX16, the expression of some of the cell cycle regulators was determined. Western blot analysis showed that knockdown of SNX16 expression enhanced the expression of G1 gatekeepers such as p21 and p18 and reduced the expression of cyclin D1, cyclin D3, and CDK6 (Fig. 2H). However, overexpression of SNX16 in SW480 cells had the opposite effects on the expression of the above mentioned key cell cycle regulators.

Analysis of apoptosis by flow cytometry revealed that SNX16 knockdown induced a significant increase in the total apoptosis rate in HT29 and LoVo cells (Fig. 2G). In contrast, ectopic SNX16 expression markedly decreased the total apoptosis rate in SW480 cells (Fig. 2G). Subsequently, we determined the expression levels of caspase-3, which plays a key role in apoptosis. Western blot analysis showed that the expression of cleaved forms of caspase-3 was upregulated in stable SNX16-knockdown HT29 and LoVo cells (Fig. 2I). Conversely, ectopic expression of SNX16 in SW480 cells led to decreased expression of cleaved forms of caspase-3 (Fig. 2I). Taken together, our results indicated that SNX16 exerts its oncogenic effect by inhibiting apoptosis and promoting the cell cycle progression of CRC cells.

### 3.4. SNX16 promotes colorectal cancer cell proliferation by activating the c-Myc signaling pathway

To explore the downstream role of SNX16 in CRC proliferation, we performed gene set enrichment analysis (GSEA) on the microarray data from GSE17536, GSE40967, GSE32323, and GSE44861. The results revealed that MYC was positively associated with high SNX16 expression in the CRC group (Fig. 3A,B). Moreover, the results of western blot and qRT-PCR analysis suggested that knockdown of SNX16 in HT29 and LoVo cells reduced the expression of c-Myc, whereas overexpression of SNX16 in SW480 cells increased the expression of c-Myc (Fig. 3C,D). Previous studies have reported that c-Myc is a powerful oncogene involved in the regulation of cell proliferation, apoptosis, differentiation, and other biological processes (Dang, 2012; Sheikh Zeineddini et al., 2019; Shen et al., 2019a; Zhang et al., 2019). Therefore, we further investigated whether the pro-proliferative effects of SNX16 are dependent on c-Myc signaling. First, we treated SNX16-overexpressing SW480 cells with a c-Myc inhibitor (10058-F4) and found that SNX16-overexpressing SW480 cells were more sensitive to the inhibitors than control cells; this increase in sensitivity was characterized by a more dramatic change in the expression of downstream cyclin D1 protein downregulation and p21 protein upregulation (Fig. 3E). Next, we constructed stable SNX16-knockdown and c-Myc-overexpressing HT29 cells. We found that ectopic expression of c-Myc significantly increased downstream cyclin D1 in HT29 cells with/without SNX16 knockdown, and decreased downstream p21 in HT29 cells with SNX16 knockdown (Fig. 3F). In addition, overexpression of c-Myc abrogated the SNX16 knockdown-mediated repression of CRC cell proliferation, whereas the inhibition of c-Myc expression significantly inhibited the proliferation of SNX16 overexpressing CRC cells compared to that of control cells. (Fig. 3G,H; Fig. S7).

Taken together, these observations confirmed that SNX16 promotes the proliferation of CRC cells by activation of the c-Myc signaling pathway.

### 3.5. The oncoprotein eEF1A2 is an interactive factor of SNX16

Using co-immunoprecipitation (Co-IP) experiments, we found that SNX16 could not interact with c-Myc (Fig. S8). Considering this inability, how does SNX16 activate the c-Myc signaling pathway? To gain insight into the molecular mechanisms by which SNX16 regulates c-Myc signaling pathway in CRC, we performed...
SNX16 promotes colorectal cancer development

Z. Shen et al.
Fig. 4. SNX16 interacts with eEF1A2 in CRC. (A, B). The proteins pulled down by using anti-SNX16 and IgG were visualized by silver staining. Co-IP of SNX16-binding proteins followed by mass spectrometry led to the identification eEF1A2 as a SNX16-binding protein. (C) The protein–protein interactions between SNX16 and eEF1A2 were confirmed by Co-IP in HT29 and LoVo cells. (D) IF analyses of colocalization of SNX16 (green) and eEF1A2 (red) in HT29 and LoVo cells (left). The quantitative values of the colocalization of SNX16 and eEF1A2 (right). The scale bars represent 10 µm.
Co-IP with an anti-SNX16 antibody to pull down potential interacting proteins from HT29 cells, followed by mass spectrometric analysis for protein identification (Fig. 4A,B). eEF1A2 was one of the most abundant proteins identified by mass spectrometry (Fig. 4B), suggesting a potential interaction between eEF1A2 and SNX16.

Human eEF1A is a member of the G protein family and one of four subunits that constitute eukaryotic elongation factor 1 (Browne and Proud, 2002; Ejiri, 2002). eEF1A2, an isoform of the eEF1A protein, is aberrantly upregulated in many tumor tissues (Cao et al., 2009; Kulkarni et al., 2007; Pinke et al., 2008; Scaggiante et al., 2012) and has been identified as a tumor-associated protein (Lee and Surh, 2009; Pellegrino et al., 2014). eEF1A2 has been reported to be involved in protein translation, the cell cycle, and apoptosis (Chang and Wang, 2007; Lee et al., 2013). Therefore, we suspect that the role of SNX16 in the inhibition of apoptosis and promotion of cell cycle progression is mediated by eEF1A2. Furthermore, Co-IP experiments using anti-SNX16 antibodies in HT29 and LoVo cells confirmed that SNX16 binds to eEF1A2, and reciprocal Co-IP further confirmed the interaction between them by using anti-eEF1A2 antibody to coprecipitate SNX16 in these cells (Fig. 4C). Immunofluorescence (IF) analyses showed that SNX16 and eEF1A2 were colocalized in the cytoplasm of HT29 and LoVo cells (Fig. 4D). Thus, we identified eEF1A2 as an interaction partner of SNX16.

3.6. SNX16 stabilizes the oncoprotein eEF1A2 by inhibiting ubiquitination

Subsequently, we evaluated the impact of SNX16 on eEF1A2 expression. The results of western blot analyses suggested that knockdown of SNX16 in HT29 and LoVo cells decreased the expression of eEF1A2, whereas ectopic expression of SNX16 in SW480 cells induced the upregulation of eEF1A2 (Fig. 5A). However, the mRNA levels of eEF1A2 were not significantly altered in cells with either anti-SNX16 knockdown or overexpression (Fig. 5B), suggesting that SNX16 might positively regulate eEF1A2 expression at the posttranscriptional level. Previous research has shown that eEF1A2 can be degraded via the ubiquitin–proteasome pathway (Sanges et al., 2012). Therefore, we hypothesized that the interaction between SNX16 and eEF1A2 might stabilize eEF1A2 by inhibiting the ubiquitin-mediated degradation of this protein. To confirm this hypothesis, we evaluated the effects of changes in SNX16 expression on eEF1A2 protein levels, either with or without the proteasome inhibitor MG132 (Wang et al., 2019). Western blot analysis showed that SNX16 no longer affected eEF1A2 expression in HT29 and SW480 cells after treatment with MG132 (Fig. 5C). Then, we further pretreated the cells with cycloheximide (CHX) (Meng et al., 2018) to block protein synthesis and to determine the stability of eEF1A2. The results indicated that the half-life of eEF1A2 expression was significantly reduced in SNX16-knockdown HT29 cells and elevated in SNX16-overexpressing SW480 cells compared with that in parental cells within the same time interval (Fig. 5D). The results of the in vitro ubiquitination assay showed a significant increase in the level of ubiquitinated eEF1A2 protein in SNX16-knockdown cells. However, overexpression of SNX16 reduced eEF1A2 ubiquitination (Fig. 5E). Taken together, these results indicated that SNX16 stabilized the expression of the oncoprotein eEF1A2 by regulating eEF1A2 ubiquitination in CRC cells.

3.7. SNX16 activates the c-Myc signaling pathway by inhibiting eEF1A2 degradation

We then examined the functional role of eEF1A2 in CRC and found that knockdown of eEF1A2 significantly inhibited growth (Fig. S9B) and colony formation ability (Fig. S9C) of HT29 cells. Moreover, SNX16 expression was unchanged following knockdown of eEF1A2 in HT29 cells (Fig. S9A), suggesting that eEF1A2 was a downstream effector of SNX16. To determine whether SNX16 regulated c-Myc expression via the eEF1A2 protein, we constructed stable SNX16-overexpressing and eEF1A2-knockdown SW480 cells. We found that knockdown of eEF1A2 expression blocked the effect of SNX16 on c-Myc expression, which suggested that eEF1A2 was a key factor for SNX16-mediated activation of the c-Myc signaling pathway (Fig. 5F). In addition, functional rescue experiments showed that the proliferative effect of SNX16 on CRC cells was reversed after knockdown of eEF1A2 (Fig. 5G,H). Thus, our results suggested that eEF1A2 is indispensable for SNX16-mediated tumor-promoting functions in CRC cells. Collectively, our data indicated that SNX16 activates the c-Myc signaling pathway by inhibiting eEF1A2 degradation.

3.8. SNX16 promotes subcutaneous xenograft tumor growth in nude mice

Based on our in vitro findings, we detected the functions of SNX16 in vivo using subcutaneous xenograft models. We performed a subcutaneous xenograft assay in nude
SNX16 promotes colorectal cancer development Z. Shen et al.

A

HT29  LoVo  SW480

SNX16

eEF1A2

Tubulin

B

HT29  LoVo  SW480

Relative mRNA expression

C

HT29  SW480

sh-SNX16  MG132

SNX16

eEF1A2

Tubulin

D

HT29  SW480

CHX(h)  sh-NC  sh-SNX16

eEF1A2

Tubulin

E

HT29  SW480

LV-SNX16  LV-NC

SNX16

eEF1A2

Tubulin

F

HT29  SW480

LV-SNX16  LV-NC

eEF1A2

Tubulin

G

O.D 570 nm

Time (Days)

H

SW480

LV-NC  LV-SNX16

sh-NC  sh-eEF1A2

Number of colonies

LV-SNX16  sh-eEF1A2

Molecular Oncology 14 (2020) 387–406 © 2019 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
mice using stable SNX16-knockdown CRC cells or stable SNX16-overexpressing CRC cells or empty vector. The results showed that knockdown of SNX16 in HT29 cells significantly suppressed tumor growth by 57% and lowered the tumor weight by 60% compared to the negative controls (Fig. 6A). Reversely, overexpression of SNX16 in SW480 cells significantly promoted tumor growth by 122% and increased the tumor weight by 103% compared to the negative controls (Fig. 6A). Immunohistochemical analysis showed that the SNX16 expression levels were positively correlated with the levels of eEF1A2, c-Myc, and Ki67 (Fig. 6B). These findings were further validated by western blot analyses of these tumor specimens (Fig. 6C).

### 3.9. SNX16 is positively related to eEF1A2 and c-Myc expression in CRC patient samples

We evaluated the correlations among SNX16, eEF1A2, and c-Myc expression in a human CRC TMA (n = 193) by IHC. Spearman’s correlation analyses revealed positive relationships among SNX16, eEF1A2 (r = 0.597; P < 0.0001), and c-Myc (r = 0.513; P < 0.0001) expression, and a positive relationship between eEF1A2 and c-Myc (r = 0.604; P < 0.0001) expression in 193 CRC specimens (Fig. 7A,B). Kaplan–Meier analysis showed that increased levels of SNX16, eEF1A2, and c-Myc expression were correlated with poor overall survival (Fig. 7C). Furthermore, multivariable Cox regression analysis showed SNX16, eEF1A2, and c-Myc expression levels were independent prognostic factors for poor survival (Table S1).

### 4. Discussion

Sorting nexins are a diverse group of proteins that contain the SNX-PX domain and play a key role in membrane trafficking (Teasdale and Collins, 2012; Worby and Dixon, 2002). Earlier studies have shown that SNXs are involved in the regulation of important signaling pathways associated with cancers, such as EGFR signaling (Kurten et al., 1996; Nishimura et al., 2012), Wnt signaling (Sun et al., 2016), TGF-β signaling (Hao et al., 2011), and so on. SNX16 is a unique SNXs family protein, consisting of a central PX domain, a potential coiled-coil domain, and a C-terminal region. The PX domain of SNX16 specifically binds to PI3P, which is mainly distributed in early endosomes and recycling endosomes, whereas the CC domain participates in the homo-dimerization of SNX16 (Choi et al., 2004; Hanson and Hong, 2003; Le Blanc et al., 2005). SNX16 has been implicated in the development of various tumors. It is reported that SNX16 was overexpressed in the blood cells of bladder cancer patients (Osman, 2006) and ovarian cancer tissues (Pharoah et al., 2013). Previous studies have suggested that SNX16 exhibited alternative splicing in certain melanoma cell lines and could interact with 32 SNPs, which is a known risk factor for prostate cancer (Tao et al., 2012; Watahiki et al., 2004). However, SNX16 was also reported to stimulate EGF receptor degradation in COS-7 cells (Choi et al., 2004) and a previous study has shown that SNX16 overexpression in MCF-7 breast cancer cell lines could decrease migration and tumor size in a mouse xenograft model (Zhang et al., 2013). In addition, Xu et al claimed that SNX16 regulated the recycling trafficking of E-cadherin and inhibited epithelial–mesenchymal transition in renal cell carcinoma (Xu et al., 2017). Nevertheless, a recent study has also shown that E-cadherin can limit reactive oxygen species-mediated apoptosis and thereby enhance tumor cell proliferation and survival (Padmanabhan et al., 2019). Hence, although SNX16 was related to cancers in various aspects, the precise expression pattern and functional roles of SNX16 in tumors remain exclusive. In this regard, we conducted a more detailed investigation of the expression, prognostic value, functional roles, and underlying mechanism of SNX16 in CRC.

In public datasets analysis, we found a significant increase of SNX16 mRNA level in primary colorectal tumors as compared to their normal mucosa. Consistently, data from our qRT-PCR, western blot, and IHC analysis displayed the substantial upregulation of...
Fig. 6. SNX16 promotes tumorigenesis in mice. (A) Subcutaneous xenograft tumor growth in nude mice was measured and compared in HT29 (sh-NC vs. sh-SNX16) and SW480 (LV-NC vs. LV-SNX16) cell lines. Results are shown as mean ± SEM, *P < 0.05, **P < 0.01, ****P < 0.0001. (B) Representative images of IHC staining of SNX16, eEF1A2, c-Myc, and Ki67 on tumor sections. Scale bar, 20 µm (40×). (C) The expression levels of the indicated proteins in these tumors were examined by western blotting. GAPDH was used as the loading control.
SNX16 in CRC tissues. What’s more, Kaplan–Meier survival analysis suggested that high SNX16 level was positively associated with poor outcomes of CRC patients, especially in stage III or IV patients with CRC. Univariate Cox regression analysis showed high SNX16 expression was associated with an increased risk of death (HR: 1.64, 95% CI: 1.079–2.500; \( P = 0.021 \)). In particular, multivariate Cox regression analysis also showed high SNX16 expression was an independent risk factor for poorer overall survival after adjustment for risk factors including differentiation and AJCC stage (HR: 1.75, 95% CI: 1.113–2.737; \( P = 0.015 \)) in patients with CRC.

On functional verification, we performed a series of \textit{in vitro} and \textit{in vivo} experiments. Our results showed that ectopic expression of SNX16 in CRC cells significantly increased cell proliferation, repressed apoptosis under stressed conditions, and reduced cell cycle arrest, while reverse regulations were seen in cells with SNX16 knockdown. In keeping with \textit{in vitro} results, subcutaneous xenograft mice model demonstrated that knockdown of SNX16 could significantly inhibit tumorigenesis, whereas ectopic expression of SNX16 significantly promoted tumorigenesis. Our gain of function and loss of function studied both \textit{in vitro} and \textit{in vivo} clearly demonstrated a carcinogenic role of SNX16 in CRC.

Since the underlying molecular mechanisms of SNX16 in CRC remain poorly identified, in our work, we conducted GSEA analysis in four GEO datasets to explore the signaling pathways related to SNX16. Using intersection analysis, we found that only MYC signature was significantly enriched in the SNX16-overexpressing CRC group in all four databases involved. The proto-oncogene c-Myc can regulate multiple genes \textit{via} both transcriptional amplification and co-factor-dependent activation/repression. c-Myc thus drives numerous biological pathways including cell proliferation (Luo et al., 2016), cell cycle (Zhang et al., 2019), metabolism (Fang et al., 2019; Shen et al., 2019a), and apoptosis (Sheikh Zeineddini et al., 2019). c-Myc expression is strictly controlled at multiple levels, including transcription, stability of both mRNA and protein, and translation (Jiang et al., 2013). As aberrantly high expression of c-Myc is a common basis of colorectal tumorigenesis (Gong et al., 2018), so we further speculated whether c-Myc was a functional downstream of SNX16 in CRC cells. Results showed overexpression of SNX16 markedly increased c-Myc expression, while knockdown of SNX16 expression significantly reduced c-Myc expression. To further verify whether c-Myc was involved in the regulation of SNX16-mediated proliferation of CRC cells, we treated CRC cells with a c-Myc inhibitor 10058-F4 to block the expression of c-Myc. Our results revealed that cells with SNX16 overexpression were much more sensitive to 10058-F4 treatment and inhibition of c-Myc could significantly block SNX16 overexpression-mediated proliferation of CRC cells. In the meantime, the tumor-suppressive functions of SNX16 knockdown were significantly reversed by c-Myc overexpression. Collectively, these data implied that the SNX16 might drive CRC cell proliferation \textit{via} regulating c-Myc signaling.

As we failed to identify the interaction between SNX16 and c-Myc, we further screened the interacting proteins of SNX16 by using immunoprecipitation–mass spectrometry. Results showed that eEF1A2 might be a novel interaction partner of SNX16. It is reported that eEF1A2 is an important protein involved in protein translation elongation, and eEF1A2 was identified as a putative oncogene in many human cancers (breast, ovary, liver, pancreas, lung, and prostate) (Giudici et al., 2019; Lee et al., 2013; Liu et al., 2019; Pellegrino et al., 2014; Worst et al., 2017; Zang et al., 2015). Researches have indicated that eEF1A2 played important roles in the regulation of various biological processes of cells, such as cell cycle, cell apoptosis, and cytoskeletal regulation. In addition, knockdown of eEF1A2 could cause G1 or G2/M arrest in the cell cycle of cancer cells according to Lee et al’s (2013) work. In hepatocellular carcinoma, Pellegrino et al. claimed that eEF1A2 protein could promote cell cycle progression (Pellegrino et al., 2014). Therefore, we suspected that eEF1A2 might be an important and functional downstream of SNX16 in CRC cells.

In our work, we found that eEF1A2 protein level upregulated following SNX16 overexpression and downregulated after SNX16 knockdown, while the mRNA level did not show consistent changes. As previous research suggested that eEF1A2 could be degraded \textit{via} the ubiquitin–proteasome pathway (Sanges et al., 2012), so we wondered SNX16 might regulate eEF1A2 expression \textit{via} regulation of ubiquitination. Using MG132 treatment, CHX treatment, and K48-linked ubiquitination detection, we identified that SNX16 could inhibit the proteasome-dependent ubiquitination of eEF1A2 protein. To further explore whether eEF1A2 is the key regulator between SNX16 and c-Myc, we constructed stable SNX16-overexpressed and eEF1A2-knockdown SW480 cells and detected c-Myc expression. Our results indicated that knockdown of eEF1A2 reversed SNX16 induced increased expression of c-Myc. On the functional rescue, results showed that knockdown of eEF1A2 could
SNX16 promotes colorectal cancer development

A

B

Pearson r = 0.597
P < 0.0001 n = 193

Pearson r = 0.513
P < 0.0001 n = 193

Pearson r = 0.604
P < 0.0001 n = 193

Log Rank = 5.673
P = 0.017

Log Rank = 5.285
P = 0.022

Log Rank = 4.961
P = 0.026

C

D

SNX16

eEF1A2

c-Myc

Proteasome

Proteasome degradation

SNX16 expression

eEF1A2 expression
c-Myc expression

Low

Low

Low

High

High

High

Time (months)

Percentage survival

Molecular Oncology 14 (2020) 387–406 © 2019 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
reverse the proliferation promoted effect driven by SNX16. Therefore, we concluded that SNX16/eEF1A2/c-Myc might be a novel regulatory axis that drives tumorigenesis in CRC.

Our study has a few disadvantages. In this study, we found the mechanism that SNX16 activates the c-Myc signaling pathway by regulating eEF1A2 expression. Nevertheless, the mechanism by which eEF1A2 regulates c-Myc signaling still remains unclear. Thus, more experiments are needed to fully elucidate the mechanism underlying eEF1A2-mediated c-Myc activation. Moreover, our work revealed that SNX16 overexpression led to decreased ubiquitination of eEF1A2 and stabilized eEF1A2 by inhibiting the ubiquitin-mediated degradation of this protein. However, the process by which SNX16 antagonizes substrate ubiquitination has not been completely understood. Therefore, further experiments are needed to elucidate the mechanism underlying the role of SNX16 in the ubiquitination of eEF1A2.

5. Conclusion

In summary, our work firstly reveals that SNX16 is overexpressed in CRC tissues and is closely associated with poor survival of CRC patients. SNX16 plays a critical role in regulating the expression of eEF1A2, then activated c-Myc singling pathway, which is responsible for the proliferation of CRC cells (Fig. 7C). Our study indicates that SNX16 may be a promising therapeutic target for the inhibition of uncontrolled CRC cell growth via the c-Myc signaling pathway.

Acknowledgements

This work was supported by the Natural Science Foundation of Guangdong Province, China (No. 201707010214); and National Natural Science Foundation of China (No. 31601023; No. 81972631). The funding institutions had no role in the study design, data collection, data analysis, interpretation, or writing of the manuscript.

Conflict of interests

The authors declare no conflict of interest.

Author contributions

HD, ZS, YF, GL, and YL were responsible for the concept and experimental design. YL and XF carried out the experiments. ML, YW, and TM contributed to clinical sample collection. YZ and XL contributed to scoring of immunohistochemical sections. ZL and ML helped with the animal study. YL performed statistical analysis. YL, YF, ZS, HD, and JW were involved in drafting and revision of the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate

This study was approved by the Institutional Research Medical Ethics Committee of Nanfang Hospital. All animal studies were performed with approval from the Institutional Animal Care and Use Committee of Nanfang Hospital.

References

Blackham S, Baillie A, Al-Hababi F, Remlinger K, You S, Hamatake R and McGarvey MJ (2010) Gene expression profiling indicates the roles of host oxidative stress, apoptosis, lipid metabolism, and intracellular transport genes in the replication of hepatitis C virus. J Virol 84, 5404–5414.

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68, 394–424.
Browne GJ and Proud CG (2002) Regulation of peptide-chain elongation in mammalian cells. Eur J Biochem 269, 5360–5368.

Cao H, Zhu Q, Huang J, Li B, Zhang S, Yao W and Zhang Y (2009) Regulation and functional role of eEF1A2 in pancreatic carcinoma. Biochem Biophys Res Commun 380, 11–16.

Chang R and Wang E (2007) Mouse translation elongation factor eEF1A-2 interacts with Prdx-I to protect cells against apoptotic death induced by oxidative stress. J Cell Biochem 100, 267–278.

Chio K, Tan Y, Chua RY, Huang D, Ng ML, Torta F, Wenk MR and Wong SH (2012) SNX3-dependent regulation of epidermal growth factor receptor (EGFR) trafficking and degradation by aspirin in epidermoid carcinoma (A-431) cells. Cell Mol Life Sci 69, 1505–1521.

Choi JH, Hong WP, Kim MJ, Kim JH, Ryu SH and Suh PG (2004) Sorting nexin 16 regulates EGF receptor trafficking by phosphorylatinginositol-3-phosphate interaction with the Phox domain. J Cell Sci 117(Pt 18), 4209–4218.

Dang CV (2012) MYC on the path to cancer. Cell 149, 22–35.

Ejiri S (2002) Moonlighting functions of polypeptide elongation factor 1: from actin bundling to zinc finger protein R1-associated nuclear localization. Biosci Biotechnol Biochem 66, 1–21.

Fang Y, Shen ZY, Zhan YZ, Feng XC, Chen KL, Li YS, Deng HJ, Pan SM, Wu DH and Ding Y (2019) CD36 inhibits beta-catenin/c-myc-mediated glycolysis through ubiquitination of GPC4 to repress colorectal tumorigenesis. Nat Commun 10, 3981.

Giudici F, Petracchi E, Nanni O, Bottin C, Pinamonti M, Zanconati F and Scaggiante B (2019) Elevated levels of eEF1A2 protein expression in triple negative breast tumorigenesis. Breast Cancer Res Treat 102, 31–41.

Kulkarni G, Turbin DA, Amiri A, Jeganathan S, Andrade-Narváro MA, Wu TD, Huntsman DG and Lee JM (2007) Expression of protein elongation factor eEF1A2 predicts favorable outcome in breast cancer. Breast Cancer Res Treat 102, 31–41.

Le Blanc I, Luyet P, Pons V, Ferguson C, Emans N, Petiot A, Mayran N, Demeulex N, Fauré J, Sadoul R et al. (2005) Endosome-to-cytosol transport of viral nucleocapsids. Nat Cell Biol 7, 653–664.

Lee MH, Choi BY, Cho YY, Lee SY, Huang Z, Kundu JK, Kim MO, Kim DJ, Bode AM, Surh Y-J et al. (2013) Tumor suppressor p16(INK4a) inhibits cancer cell growth by downregulating eEF1A2 through a direct interaction. J Cell Sci 126(Pt 8), 1744–1752.

Lee M and Surh Y (2009) eEF1A2 as a putative oncogene. Ann N Y Acad Sci 1171, 87–93.

Liu H, Liu Z, Chen CXQ, Magill S, Jiang Y and Liu Y (2006) Inhibitory regulation of EGF receptor degradation by sorting nexin 5. Biochem Biophys Res Commun 342, 537–546.

Liu S, Hausmann S, Carlson SM, Fuentes ME, Francis JW, Pillai R, Lofgren SM, Hulea L, Tandoc K, Lu J et al. (2019) METTL13 methylation of eEF1A increases translational output to promote tumorigenesis. Cell 176, 491–504.

Luo J, Zhang C, Wang C, Li L, Li C, Li Q, Zhang M and Wu Q (2016) MIZ-1 promotes the proliferation of esophageal cancer cells via suppression of p21 and release of p21-arrested cyclin D1. Oncol Rep 35, 3532–3540.

Luo Y, Tsuchiya KD, Il Park D, Fausel R, Kannegur S, Welch P, Dzieciatkowski S, Wang J and Grady WM (2013) RET is a potential tumor suppressor gene in colorectal cancer. Oncogene 32, 2037–2047.

Meng X, Liu X, Guo X, Jiang S, Chen T, Hu Z, Liu H, Bai Y, Xue M, Hu R et al. (2018) FBXO38 mediates PD-1 ubiquitination and regulates anti-tumour immunity of T cells. Nature 564, 130–135.
SNX16 promotes colorectal cancer development

Muller MF, Ibrahim AE and Arends MJ (2016) Molecular pathological classification of colorectal cancer. *Virchows Arch* **469**, 125–134.

Nagarajan A, Malvi P and Wajapeyye N (2016) Oncogene-directed alterations in cancer cell metabolism. *Trends Cancer* **2**, 365–377.

Ni W, Zhang Y, Zhan Z, Ye F, Liang Y, Huang J, Chen K, Chen L and Ding Y (2017) A novel IncRNA uc.134 represses hepatocellular carcinoma progression by inhibiting CUL4A-mediated ubiquitination of LATS1. *J Hematol Oncology* **10**, 91.

Nishimura Y, Takiguchi S, Yoshioka K, Nakabeppu Y and Itoh K (2012) Silencing of SNX1 by siRNA stimulates the ligand-induced endocytosis of EGFR and increases EGFR phosphorylation in gefitinib-resistant human lung cancer cell lines. *Int J Oncol* **41**, 1520–1530.

Oman I (2006) Novel blood biomarkers of human urinary bladder cancer. *Clin Cancer Res* **12**, 3374–3380.

Padmanaban V, Krol I, Su hail Y, Szcerba BM, Aceto N, Bader JS and Ewald AJ. (2019) E-cadherin is required for metastasis in multiple models of breast cancer. *Nature* **573**, 439–444.

Pellegrino R, Calvisi DF, Neumann O, Kolluru V, Wesely J, Chen X, Wang C, Wuestefeld T, Ladu S, Elgohary N et al. (2014) EEF1A2 inactivates p53 by way of PI3K/AKT/mTOR-dependent stabilization of IMD4 in hepatocellular carcinoma. *Hepatology* **59**, 1886–1899.

Pharoah PDP, Tsai Y, Ramus SJ, Phelan CM, Goode EL, Lawrenson K, Buckley M, Fridley BL, Tyer JP, Shen H et al. (2013) GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. *Nat Genet* **45**, 362–370.

Pinke DE, Kalloger SE, Francetic T, Huntsman DG and Lee JM (2008) The prognostic significance of elongation factor eEF1A2 in ovarian cancer. *Gynecol Oncol* **108**, 561–568.

Sanges C, Scheuermann C, Zahedi RP, Sickmann A, Lamberti A, Migliaccio N, Baljuls A, Marra M, Zappavigna S, Reinders J et al. (2012) Raf kinases mediate the phosphorylation of eukaryotic translation elongation factor 1A and regulate its stability in eukaryotic cells. *Cell Death Dis* **3**, e276.

Scaggiante B, Dapass B, Bonin S, Grassi M, Zennaro C, Farra R, Cristiano L, Siracusano S, Zanconati F, Giansante C et al. (2012) Dissecting the expression of EEF1A1/2 genes in human prostate cancer cells: the potential of EEF1A2 as a hallmark for prostate transformation and progression. *Br J Cancer* **106**, 166–173.

Sheik Zineeddini N, Bashash D, Safaroghli Azar A, Riyahi N, Shabestari RM, Janzamin E and Safa M (2019) Suppression of c-Myc using 10058–F4 exerts caspase-3-dependent apoptosis and intensifies the antileukemic effect of vincristine in pre-B acute lymphoblastic leukemia cells. *J Cell Biochem* **120**, 14004–14016.

Shen Y, Zhao S, Wang S, Pan X, Zhang Y, Xu J, Jiang Y, Li H, Zhang Q, Gao J et al. (2019a) SIP/SIPR3 axis promotes aerobic glycolysis by YAP/c-MYC/PGAM1 axis in osteosarcoma. *EBioMedicine* **40**, 210–223.

Shen Z, Feng X, Fang Y, Li Y, Li Z, Zhan Y, Lin M, Li G, Ding Y and Deng H (2019b) POTEE drives colorectal cancer development via regulating SPHK1/p65 signaling. *Cell Death Dis* **10**, 863.

Sun L, Hu X, Chen W, He W, Zhang Z and Wang T (2016) Sorting nexin 27 interacts with Fzd7 and mediates Wnt signalling. *Biosci Rep* **36**, e296.

Tao S, Wang Z, Feng J, Hsu F, Jin G, Kim S, Zhang Z, Gronberg H, Zheng LS, Isaacs WB et al. (2012) A genome-wide search for loci interacting with known prostate cancer risk-associated genetic variants. *Carcinogenesis* **33**, 598–603.

Teasdale RD and Collins BM (2012) Insights into the PX (phox-homology) domain and SNX (sorting nexin) protein families: structures, functions and roles in disease. *Biochem J* **441**, 39–59.

Wang H, Deng G, Ai M, Xu Z, Mou T, Yu J, Liu H, Wang S and Li G (2019) Hsp90ab1 stabilizes LRP5 to promote epithelial-mesenchymal transition via activating of AKT and Wnt/beta-catenin signaling pathways in gastric cancer progression. *Oncogene* **38**, 1489–1507.

Watahiki A, Waki K, Hayatsu N, Shiraki T, Kondo S, Nakamura M, Sasaki D, Arakawa T, Kawai J, Harbers M et al. (2004) Libraries enriched for alternatively spliced exons reveal splicing patterns in melanocytes and melanomas. *Nat Methods* **1**, 233–239.

Worby CA and Dixon JE (2002) Correction: Sorting out the cellular functions of sorting nexins. *Nat Rev Mol Cell Biol* **3**, 919–931.

Worst TS, Waldbillig F, Abdelhadi A, Weis CA, Gottschalt M, Steidler A, von Hardenberg J Michel MS and Erben P (2017) The EEF1A2 gene expression as risk predictor in localized prostate cancer. *BMC Urol* **17**, 86.

Xu J, Zhang L, Ye Y, Shan Y, Wan C, Wang J, Pei D, Shu X and Liu J (2017) SNX16 regulates the recycling of E-cadherin through a unique mechanism of coordinated membrane and cargo binding. *Structure* **25**, 1251–1263.

Zang W, Wang Y, Wang T, Du Y, Chen X, Li M and Zhao G (2015) miR-663 attenuates tumor growth and invasiveness by targeting EEF1A2 in pancreatic cancer. *Mol Cancer* **14**, 37.

Zhang F, Li K, Yao X, Wang H, Li W, Wu J, Li M, Zhou R, Xu L and Zhao L (2019) A miR-567-PIK3AP1-PI3K/AKT-c-Myc feedback loop regulates tumour...
growth and chemoresistance in gastric cancer. 

*EBioMedicine* **44**, 311–321.

Zhang L, Qin D, Hao C, Shu X and Pei D (2013) SNX16 negatively regulates the migration and tumorigenesis of MCF-7 cells. *Cell Regen* **2**, 2–3.

**Supporting information**

Additional supporting information may be found online in the Supporting Information section at the end of the article.

**Fig. S1.** Expression of SNX16 in data from the Oncomine database.

**Fig. S2.** Correlation of SNX16 expression with patient survival in CRC.

**Fig. S3.** qRT-PCR and Western blot analyses of SNX16 expression in CRC cell lines.

**Fig. S4.** Images of EdU assay in indicated cell lines, related to Fig. 2D. Scale bar, 50 μm.

**Fig. S5.** Knockdown or overexpression of SNX16 did not affect CRC cells migration.

**Fig. S6.** Cell cycle analysis. Cells were enriched in G1 phase by incubation with 0.8 mM l-mimosine for 24 h.

**Fig. S7.** Cell survival assays were used to determine the vulnerability of cells (LV-NC vs. LV-SNX16) to 10058-F4 treatment.

**Fig. S8.** Co-IP was performed to detect the interaction between SNX16 and c-Myc in HT29 cells.

**Fig. S9.** Knockdown of eEF1A2 inhibited CRC cells proliferation *in vitro*.

**Table S1.** Univariable and multivariable Cox regression analyses of the association of clinical characteristics with the prognosis of 193 CRC patients.

**Table S2.** Antibodies used for Western blotting, coimmunoprecipitation and immunofluorescence.

**Table S3.** Nucleotide sequences of the primers used in this study.